Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma

• Published in: Scientific reports 2018-10, Vol.8 (1), p.15674-10, Article 15674
• Main Authors: Mohamed, Abdalla D., Shah, Nupur, Hettmer, Simone, Vargesson, Neil, Wackerhage, Henning
• Format: Article
• Language: English
• Subjects: 13; 13/1; 13/106; 13/109; 13/44; 13/95; 14/19; 38/77; 692/308/2056; 692/308/3187; 82/80; Adaptor Proteins, Signal Transducing - metabolism; Animals; Cancer; Cell Line; Cyclin-Dependent Kinase Inhibitor p16 - metabolism; DNA microarrays; Gene expression; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humanities and Social Sciences; Humans; Hyperactivity; K-Ras protein; Mice, Transgenic; multidisciplinary; Mutation; Myoblasts; Oncogenes; p53 Protein; Phosphoproteins - metabolism; Proto-Oncogene Proteins p21(ras) - genetics; Rhabdomyosarcoma; Rhabdomyosarcoma, Embryonal - genetics; Satellite cells; Science; Science (multidisciplinary); Transcription; Transcription Factors; Tumors; YAP-Signaling Proteins; Yes-associated protein
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-33852-7

Persistent hyperactivity of the Hippo effector YAP in activated satellite cells is sufficient to cause embryonal rhabdomyosarcoma (ERMS) in mice. In humans, YAP is abundant and nuclear in the majority of ERMS cases, and high YAP expression is associated with poor survival. However, YAP1 is rarely mutated in human ERMS. Instead, the most common mutations in ERMS are oncogenic RAS mutations. First, to compare YAP1 S127A and KRAS G12V -driven rhabdomyosarcomas, we re-analysed gene expression microarray datasets from mouse rhabdomyosarcomas caused by these genes. This revealed that only 20% of the up or downregulated genes are identical, suggesting substantial differences in gene expression between YAP and KRAS-driven rhabdomyosarcomas. As oncogenic RAS has been linked to YAP in other types of cancer, we also tested whether KRAS G12V alone or in combination with loss of p53 and p16 activates YAP in myoblasts. We found that neither KRAS G12V alone nor KRAS G12V combined with loss of p53 and p16 activated Yap or Yap/Taz-Tead1–4 transcriptional activity in C2C12 myoblasts or U57810 cells. In conclusion, whilst oncogenic KRAS mutation might activate Yap in other cell types, we could find no evidence for this in myoblasts because the expression of KRAS G12V expression did not change Yap/Taz activity in myoblasts and there was a limited overlap in gene expression between KRAS G12V and YAP1 S127A -driven tumours.